VIM0423
Our lead program, VIM0423 is a novel oral therapeutic for dystonia that selectively targets muscarinic cholinergic receptors in the brain. These receptors are known to be involved in dystonia and related movement disorders but targeting them has been limited by poor tolerability. VIM0423 has been designed to maximize both efficacy and tolerability to deliver effective therapy for all dystonia patients.
VIM0423 has been granted Fast Track designation by the FDA and is currently being evaluated in a Phase 1 clinical trial.